The Saudi Vaccine and Biomanufacturing Center (SVBC), the first of its kind in the Middle East, broke ground at KAUST on December 15. The center will develop vaccines and biopharmaceutical products under good manufacturing practice (GMP) standards. It is a joint project championed by the Ministry of Energy, Industry and Mineral Resources through the Industrial Clusters Program and supported by KACST. Why it matters: The center will serve as a national platform for pharmaceutical innovation and address epidemic risks in the Kingdom, such as MERS-CoV.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
MBZUAI is hosting a free webinar on August 4th from 6-7pm titled ‘How does AI help fight the COVID-19 pandemic?’. The webinar will be led by Dr. Mohammad Yaqub, Assistant Professor at MBZUAI, and will discuss the role of AI before, during, and after a pandemic. Registration is available at www.mbzuai.ac.ae/aitalks. Why it matters: This webinar aims to educate the public on the potential of AI in addressing pandemics, aligning with MBZUAI's social responsibility efforts in the UAE.
Dr. Mohammad Yaqub from MBZUAI will present AI solutions used to combat the COVID-19 pandemic, addressing healthcare consequences, social, economic, and policy-making decisions. The talk will cover the applications of AI and also discuss challenges like privacy, data needs, generalizability, data noise, and human acceptance. Yaqub's background includes a DPhil from the University of Oxford in Biomedical Engineering and research at the Institute of Biomedical Engineering, focusing on machine learning solutions for medical problems. Why it matters: This talk highlights the important role of AI in addressing pandemics and the ethical considerations that come with its application in healthcare and policymaking.
A KAUST scientist led a global call for climate solutions, published simultaneously by 14 academic journals and released at COP29. The publication, prepared by 18 scientists, urges international governments to deploy microbial 'vaccines' against climate change. Six simple 'vaccine' examples are outlined, including carbon sequestration boosters and methane busters. Why it matters: This coordinated effort highlights the urgency of addressing climate change and KAUST's leading role in microbial solutions.
KAUST held its first bio-entrepreneurship ideation workshop, "Ignite Bio", for Biological and Environmental Science and Engineering students and postdoctoral fellows. Speakers from Noor Diagnostics and Discovery, Cellestia BioTech, Kyanos Biotechnology and SaudiVax shared their experiences about the startup journey. Saudi-based startups highlighted the need for services and products not currently available in the Kingdom, such as genetic diagnostic testing and local vaccine production. Why it matters: The workshop and the highlighted startups signal growing interest and opportunities for biotech innovation and entrepreneurship within Saudi Arabia.
MBZUAI is developing AI-powered applications to help reduce malaria's impact in Indonesia, supported by Sheikh Mohamed bin Zayed Al Nahyan's Reaching the Last Mile initiative. The applications use sensory data fusion to create "digital twins" for precise weather forecasting and real-time environmental representation. AI and clustering analysis identify recurring features contributing to malaria outbreaks, enabling preventative measures and early treatment. Why it matters: This project demonstrates AI's potential in combating climate-sensitive diseases and improving public health in vulnerable regions.